Moleculin Biotech’s (MBRX) Buy Rating Reiterated at HC Wainwright

Moleculin Biotech (NASDAQ:MBRX)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They presently have a $8.00 target price on the stock.

Other equities analysts have also issued reports about the company. Maxim Group lowered Moleculin Biotech from a “buy” rating to a “hold” rating in a research report on Wednesday, February 12th. StockNews.com initiated coverage on shares of Moleculin Biotech in a research note on Thursday, March 13th. They set a “sell” rating on the stock.

Moleculin Biotech Stock Performance

Shares of NASDAQ MBRX traded down $0.04 during mid-day trading on Monday, reaching $1.05. 347,955 shares of the company were exchanged, compared to its average volume of 6,233,274. Moleculin Biotech has a 52 week low of $0.40 and a 52 week high of $6.23. The company’s 50 day moving average price is $1.36 and its 200 day moving average price is $2.02.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.